OptionsHouse

Options Trading News

October 2, 2013  Wed 8:11 AM CT

CELG: SEE CHART GET CHAIN FIND STRATEGIES
Celgene and Merck are crosstown rivals. One's always innovating, putting money to work in a variety of biotechs, buying when the time is right. It's always going for the blockbuster, trying to press, press, press.

The other is trying to cut its way to success by firing, trimming, and hoping to eke out money as its new products fail to ignite or just fail. It's unoriginal and staid--just trying to pay that dividend.

The first is obviously Celgene, and the second is Merck, which managed to pop its stock with an announcement that is laying off a bunch of people. It's a second reduction in force for this obviously bloated company.

TheStreet.com logoBut the first used to be Merck. It used to be the ultimate in original thinking and new products. Not anymore. Even its acquisition of the gigantic Schering-Plough in 2009 seems to have gotten it nothing significant that I can see. I had hoped that at least the company would follow in the footsteps of Pfizer and spin off animal health, but even that is apparently too radical.

Either way, I think that Merck's a sell, not a buy. The market wants growth and new drugs. If it wants yield, it can get it from Con Ed. Disappointing, again.

Disclosures:
Cramer's charitable trust has no positions in the stocks mentioned.
Share this article with your friends


Related Stories

CELG

Trades bet on summer rally in Celgene

July 7, 2016

The drug developer is down 7 percent in the last month, but traders are betting on gains in the next six weeks.

OptionsHouse

TRADING WEEKLY OPTIONS

The fastest money in the market
View full report »

Premium Services

Education & Strategy

Know thyself before trading

All too often people jump into market without considering some basic guidelines that have as much to do about themselves...

View more education articles »